Amgen reports non-GAAP EPS for the last three months of 2023 up 15% to $4.71, with non-GAAP operating margin improving 0.8 points to 46.7% on revenues up 20% to $8.2 billion.

The biotech group saw its product sales rise by 23% in volume terms, driven by double-digit growth for its Blincyto, Evenity, Repatha and Prolia products, while average selling prices contracted by 0.3%.

With full-year 2023 adjusted EPS of $18.65 and revenues of $28.2 billion, Amgen expects to achieve target ranges of $18.90-20.30 and $32.4-33.8 billion respectively for the year ahead.

Copyright (c) 2024 CercleFinance.com. All rights reserved.